Cardiology Letters 2022, 31(3):178-183
The relationship between cardiac resynchronization therapy and serum levels of copeptin
- East-Slovak Institute of Cardiovascular Diseases, Department of Arrhythmias, Kosice, Slovakia
Background: Chronic heart failure (CHF) is a complex syndrome characterized by an abnormal neurohormonal activation, including arginine vasopressin (AVP). Copeptin is an indicator of AVP activation, which levels are elevated in CHF and have prognostic importance. Cardiac resynchronization therapy (CRT) is an important device therapy for patients with advanced CHF, left ventricular (LV) systolic dysfunction and evidence of electromechanical dyssynchrony. The aim of the present study was to determine the possible relationship between CRT and serum copeptin levels.
Methods: We included CRT patients with ischemic as well as nonischemic etiology of CHF. The levels of copeptin were measured at baseline and 12 months respectively after CRT implantation. Echocardiography was also performed pre and 12 months post CRT implantation. A CRT response was defined as a ≥ 15% reduction in LV end-systolic volume (LVESV).
Results: The study population consisted of 41 patients. The mean copeptin level was 20.50 ± 15.77 pmol/l. Copeptin levels positively correlated with New York Heart Association class, left atrial diameter, creatinine levels and NT-proBNP levels. CRT responders have significant reduction in copeptin levels from baseline to 12 months (from 16.96 ± 12.80 pmol/l to 6.20 ± 6.44 pmol/l, p < 0.001). No significant changes in copeptin levels were observed in CRT nonresponders. Reduction > 45% in copeptin levels was significantly associated with CRT-response (OR 6.72, 95% CI 1.01 - 18.11, p = 0.045). Fig. 1, Tab. 2, Ref. 23, on-line full text (Free, PDF) www.cardiologyletters.sk Conclusion: The copeptin serum levels can be a useful biomarker in the evaluation of the CRT response.
Kľúčové slová: heart failure; biomarker; copeptin; cardiac resynchronization; responder
Uverejnené: March 1, 2022 Zobraziť citáciu
Referencie
- Kadota M, Ise T, Yagi S, et al. Response prediction and influence of tolvaptan in chronic heart failure patients considering the interaction of the renin-angiotensin-aldosterone system and arginine vasopressin. Int Heart J. 2016;57:461-465.
Prejsť k pôvodnému zdroju... - Holwerda DA. A glycopeptide from the posterior lobe of pig pituitaries. 1. Isolation and characterization. Eur J Biochem. 1972;28:334-339.
Prejsť k pôvodnému zdroju... - Morawiec B, Kawecki D. Copeptin: a new marker in cardiology. J Cardiovasc Med (Hagerstown). 2013;14:1- 25.
Prejsť k pôvodnému zdroju... - Morgenthaler NG. Copeptin: A biomarker of cardiovascular and renal function. Congest Heart Fail. 2010;16 (Suppl I):37-44.
Prejsť k pôvodnému zdroju... - Xu L, Liu X, Wu S, et al. The clinical application value of the plasma copeptin level in the assessment of heart failure with reduced left ventricular ejection fraction. A cross-sectional study. Medicine (Baltimore). 2018;97:e12610.
Prejsť k pôvodnému zdroju... - Tentzeris I, Jarai R, Farhan S, et al. Complementary role of copeptin and high-sensitivity troponin in predicting outcome in patients with stable chronic heart failure. Eur J Heart Fail. 2011;13:726733.
Prejsť k pôvodnému zdroju... - Miller WL, Hartman KA, Grill DE, et al. Serial measurements of midregion proANP and copeptin in ambulatory patients with heart failure: incremental prognostic value of novel biomarkers in heart failure. Heart. 2012;98:389-394.
Prejsť k pôvodnému zdroju... - Stoiser B, Mörtl D, Hülsmann M, et al. Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure. Eur J Clin Invest. 2006;36:771-778.
Prejsť k pôvodnému zdroju... - Masson S, Latini R, Carbioneri E, et al, GISSI-HF Investigators. The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI-heart failure (GISSI-HF) trial. Eur J Heart Fail. 2010;12:338-347.
Prejsť k pôvodnému zdroju... - Neuhold S, Huelsmann M, Strunk G, et al. Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure. J Am Coll Cardiol. 2008;52:266-272.
Prejsť k pôvodnému zdroju... - McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33:1787-1847.
- St John Sutton MG, Plappert T, Abraham WT, et al and for the Multicenter InSync Randomized Clinical Evaluation (MIRACLE) Study Group. Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure. Circulation. 2003; 07:1985-1990.
Prejsť k pôvodnému zdroju... - Tang AS, Wells GA, Talajic M, et al. ResynchronizationDefibrillation for Ambulatory Heart Failure Trial (RAFT) Investigators. Cardiac resynchronization therapy for mild-tomoderate heart failure. N Engl J Med. 2010;363:2385-2395.
Prejsť k pôvodnému zdroju... - Moss AJ, Hall WJ, Cannom DS, et al. MADIT-CRT Trial Investigators. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361:1329-1338.15. Bristow MR, Saxon LA, Boehmer J, et al. Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004; 350: 2140 - 2150.
Prejsť k pôvodnému zdroju... - Bose A, Truong QA, Singh JP. Biomarkers in electrophysiology: role in arrhythmias and resynchronization therapy. J Interv Card Electrophysiol. 2015;43:31 44.
Prejsť k pôvodnému zdroju... - Serradeil-Le Gal C, Wagnon J, Valette G, et al. Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands. Prog Brain Res. 2020;139:197-210.
Prejsť k pôvodnému zdroju... - Chatterjee K. Neurohormonal activation in congestive heart failure and role of vasopressin. Am J Cardiol. 2005;95:8B-13B.
Prejsť k pôvodnému zdroju... - Baumann G, Dingman JF. Distribution, blood transport and degradation of antidiuretic hormone in man. J Clin Invest. 1976;57:1109-1116.
Prejsť k pôvodnému zdroju... - Zhong Y, Wang R, Yan L, et al. Copeptin in heart failure: review and meta-analysis. Clin Chim Acta. 2017;475: 36-43.
Prejsť k pôvodnému zdroju... - Zhang P, Wu X, Li G, et al. Prognostic role of copeptin with allcause mortality after heart failure: a systematic review and meta-analysis. Therapeutic and Clinical Risk Management 2017;13:49- 8.
Prejsť k pôvodnému zdroju... - Lasota B, Mizia-Stec. Copeptin in heart failure. Research Reports in Clinical Cardiology. 2014;5:13- 144.
Prejsť k pôvodnému zdroju... - Bhandari SS, Loke I, Davies JE, et al. Gender and function influence plasma levels of copeptin in healthy individuals. Clin Sci (Lond). 2009;116:257-263.
Prejsť k pôvodnému zdroju...

